Developing Your Commercial Strategy in Phases II-III
As market access challenges intensify, pharma companies are beginning their commercialization planning much earlier in the product lifecycle. Advance market research helps manufacturers learn which differentiators are necessary for a successful launch—information that ultimately informs the decision to move forward with an asset.
In this webinar, we’ll examine how pharma companies can use data and insights to make the most of this critical stage. We’ll discuss how targeted investments in Phase 2B/3 can provide an early look at access barriers throughout the patient journey. We’ll share how manufacturers can determine which stakeholders matter most, what they need to hear, and how to effectively reach them to secure access. With this foundation, manufacturers can reverse-engineer a successful go-to-market plan.
You will learn:
How early identification of payer priorities can inform your Phase III endpoints and result in a stronger value story
Why understanding access roadblocks and the patient’s path to diagnosis helps your team allocate resources effectively
How segmenting payers by attributes helps your team develop a payer prioritization and contracting strategy for sales